Glen Oaks, New York 11004

  • Schizophrenia

Purpose:

This study will evaluate electroconvulsive therapy (ECT) in patients who have not responded adequately to clozapine.


Study summary:

ECT augmentation of clozapine will be compared to clozapine monotherapy in schizophrenic patients who continue to have psychotic symptoms despite optimal treatment with clozapine.


Criteria:

Inclusion criteria: - Receiving at least two 400 mg doses of chlorpromazine equivalents for at least 4 weeks (may include newer antipsychotics) - Having substantial psychotic symptoms despite at least 12 weeks of treatment (at least 8 weeks at a consistent dose)


NCT ID:

NCT00042224


Primary Contact:

Principal Investigator
Georgios Petrides, MD
New Jersey Medical School


Backup Contact:

N/A


Location Contact:

Glen Oaks, New York 11004
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.